Parathyroid hormone (1-34) alone was better than parathyroid hormone plus alendronate in men with osteoporosis

May 2004
ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p63
Academic Journal
This article presents a study to determine whether parathyroid hormone (1-34) (PTH) plus alendronate more effective than monotherapy with either agent for increasing bone mineral density (BMD) at the lumbar spine, in men 46 to 85 years of age with osteoporosis. Increase in BMD at the lumbar spine was greater in the PTH-alone group than in the alendronate-alone or combination groups (Table). The increase in BMD at the lumbar spine was also greater in the combination group than in the alendronate-alone group. PTH alone was more effective than PTH plus alendronate or alendronate alone for increasing bone mineral density at the lumbar spine.


Related Articles

  • Parathyroid Hormone in the Treatment of Osteoporosis. Fujita, T. // BioDrugs;2001, Vol. 15 Issue 11, p721 

    Parathyroid hormone (PTH), especially intact human PTH [hPTH(1-84)] and its various fragments [hPTH(1-31), (1-34), (1-36), (1-38) and their modifications], has been used for the treatment of osteoporosis over the last 10 years. Although chronic continuous excess of PTH markedly increases bone...

  • Recombinant Full-Length Parathyroid Hormone (1-84). Moen, Marit D.; Scott, Lesley J // BioDrugs;2007, Vol. 21 Issue 3, p205 

    The article discusses the importance of recombinant full-length parathyroid hormone in treating osteoporosis. Osteoporosis occurs when the rate of bone resorption exceeds the rate of bone formation. The resulting loss of bone mass and strength can lead to fragility fractures. Available...

  • Future Developments in Osteoporosis Therapy. Ng, K. W. // Endocrine, Metabolic & Immune Disorders - Drug Targets;Dec2009, Vol. 9 Issue 4, p371 

    Anti-resorptives that prevent osteoclasts from resorbing bone are the mainstay of treatment for osteoporosis, while parathyroid hormone is the only agent available that stimulates osteoblasts to form bone. Advances in knowledge about metabolic pathways in bone cell biology have identified...

  • bmj updates.  // BMJ: British Medical Journal (International Edition);8/12/2006, Vol. 333 Issue 7563, preceding p311 

    The article provides a summary of the article "Parathyroid hormone for the treatment of osteoporosis: a systematic review," by A. Cranney, et al. The study evaluated the use of parathyroid hormone as a treatment for osteoporosis in women. The research found that the use of parathyroid hormone...

  • THE EARLY BIOCHEMICAL RESPONSE OF ELDERLY PATIENTS WITH OSTEOPOROSIS TO PARATHYROID HORMONE THERAPY. Casey, M. C.; Connolly, C.; Healy, M.; Lam, M.; Maher, N.; Kirby, C.; Cunningham, C.; Coakley, D.; Walsh, J. C. // Age & Ageing;Jul2005 Supplement1, Vol. 34, pi7 

    Discusses research being done on the early biochemical response to parathyroid hormone therapy in elderly patients with osteoporosis. Reference to a study by M. C. Casey and colleagues, presented at the autumn meeting of the British Geriatrics Societies in October 2004; Biochemical markers...

  • Recombinant human parathyroid hormone. Reeve, Jonathan // BMJ: British Medical Journal (International Edition);2/23/2002, Vol. 324 Issue 7335, p435 

    Editorial. Reports that the United States Food & Drug Administration voted in favor of the recombinant parathyroid hormone for the treatment of menopausal osteoporosis. Finding that the hormone injections increase bone mass and strength; Description of how data from animal studies helped...

  • Bears, bones and osteoporosis.  // Active Living;Nov2006, Vol. 15 Issue 6, p29 

    The article discusses a review by the Scientific Advisory Council of Osteoporosis Canada which concluded that treatment with parathyroid hormone could be effective for osteoporosis. Parathyroid hormone is produced by black bears after hibernation to overcome bone loss generated by several months...

  • New options in treating osteoporosis. LoBuono, Charlotte // Drug Topics;5/5/2003 Supplement, Vol. 147 Issue 9, p9S 

    Focuses on the alternative option in the treatment of osteoporosis called teriparatide, a recombinant form of human parathyroid hormone. Recommended administration; Most common adverse effects; Other therapies for osteoporosis.

  • Teriparatide (hPTH-[1-34]). Ashworth, L.E. // Formulary;Mar2002, Vol. 37 Issue 3, p129 

    Examines the efficacy of teriparatide (hPTH-[1-34]) in treating osteoporosis. Pharmacological properties of teriparatide; Increase in the total-body bone mass density; Adverse effects of the drug.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics